Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 24, 2014; 4(2): 57-80
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.57
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.57
Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies
Andrew Scott Mathis, Hoytin Lee Ghin, Pharmacy Department, Monmouth Medical Center, Long Branch, NJ 07740, United States
Gwen Egloff, School of Pharmacy, University of Connecticut, Storrs, CT 06268, United States
Author contributions: All authors have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published.
Correspondence to: Andrew Scott Mathis, RPh, BS, PharmD, Pharmacy Department, Monmouth Medical Center, 300 Second Avenue, Long Branch, NJ 07740, United States. smathis@barnabashealth.org
Telephone: +1-732-9236753 Fax: +1-732-9236757
Received: February 8, 2014
Revised: March 24, 2014
Accepted: May 14, 2014
Published online: June 24, 2014
Processing time: 161 Days and 21.4 Hours
Revised: March 24, 2014
Accepted: May 14, 2014
Published online: June 24, 2014
Processing time: 161 Days and 21.4 Hours
Core Tip
Core tip: Mycophenolic acid derivatives have been used successfully to facilitate late calcineurin inhibitor withdrawal to improve short-term renal function in kidney transplantation. The benefit carries an increased risk of acute cellular rejection. Sirolimus and everolimus are also options, but have comparatively less evidence and carry and increased risk of proteinuria, which is dependent on baseline renal function.